Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective

Niklas Gebauer*, Harald Biersack, Ann Cathrin Czerwinska, Janina Schemme, Tim Tristan Hardel, Veronica Bernard, Dirk Rades, Hendrik Lehnert, Kim Barbara Luley, Christoph Thorns

*Corresponding author for this work
1 Citation (Scopus)
Original languageEnglish
JournalLeukemia and Lymphoma
Issue number1
Pages (from-to)226-229
Number of pages4
Publication statusPublished - 02.01.2016

Cite this